Risk of hepatocellular carcinoma in cirrhotic hepatitis B virus patients during nucleoside/nucleotide analog therapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1872-034x|45|8|872-879

ISSN： 1386-6346

Source： HEPATOLOGY RESEARCH, Vol.45, Iss.8, 2015-08, pp. : 872-879

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Factors associated with the effect of interferon‐α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 12, 2015-12 ,pp. : 1195-1202

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk factors of hepatocellular carcinoma development in non‐cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 7, 2015-07 ,pp. : 1183-1189

John Wiley & Sons Inc

Access to resources Recommend Favorite

Single Nucleotide Polymorphisms Associated with Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection

By  

Intervirology, Vol. 48, Iss. 1, 2005-03 ,pp. : 10-15

Karger

Access to resources Recommend Favorite

Impact of Peginterferon Maintenance Therapy on the Risk of Developing Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Virus

By  

Oncology, Vol. 78, Iss. 1, 2010-07 ,pp. : 11-16

Karger

Access to resources Recommend Favorite

Letter: pre‐ and post‐operative anti‐viral therapy is important for patients with hepatitis B virus‐related hepatocellular carcinoma

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 8, 2015-04 ,pp. : 789-790

John Wiley & Sons Inc

Access to resources Recommend Favorite